Should medical students be routinely offered BCG vaccination?

Medical Journal of Australia

Volumn 185, Issue 6, 2006, Pages 324-326

  Graham, Maryza ^a   Howley, Tanya M ^b   Pierce, Robert J ^a   Johnson, Paul D ^a,c  

^a AUSTIN HEALTH   (Australia)

^b BALLARAT HEALTH SERVICES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIA; BCG VACCINATION; DOSE RESPONSE; DRUG COST; DRUG SAFETY; HEALTH CARE PERSONNEL; HEPATITIS; HUMAN; KELOID; MEDICAL SCHOOL; MEDICAL STUDENT; MIGRANT WORKER; MULTIDRUG RESISTANCE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PREVALENCE; SCREENING TEST; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33749495993     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00587.x     Document Type: Article

References (30)

1. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138.
2. Vynnycky E, Fine PEM. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000, 152: 247-263.
3. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: NHMRC, 2003: 232. http://www1.health.gov.au/immhandbook/pdf/handbook.pdf (accessed Aug 2006).
4. Management, prevention and control of tuberculosis: guidelines for health care providers 2002-2005. Melbourne: State Government of Victoria, Department of Human Services, 2002: 34. http://www.health.vic.gov.au/ideas/diseases/tb_mgmt_guide.htm. (accessed Aug 2006).
5. Committee of Deans of Australian Medical Schools (CDAMS). Guidelines for infectious diseases policies and programs for medical students. http://www.cdams.org.au/policy.html (accessed Aug 2006).
6. Stuart RL, Bennett NJ, Forbes AB, Grayson ML. Assessing the risk of tuberculosis infection among healthcare workers: the Melbourne Mantoux Study. Melbourne Mantoux Study Group. Med J Aust 2001; 174: 569-573.
7. Wilkins D, Woolcock AJ, Cossart YE. Tuberculosis: medical students at risk. Med J Aust 1994; 160: 395-397.
8. Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356: 461-465.
9. Diel R, Seidler A, Nienhaus A, et al. Occupational risk of tuberculosis transmission in a low incidence area. Respir Res 2005; 6: 35.
10. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001.
11. Cobelens FG, Draayer-Jansen EW, Schepp-Beelen JC, et al. [Limited tuberculin screening participation among travellers to countries with high tuberculosis incidence: reason to consider BCG vaccination for some travellers] [Dutch]. Ned Tijdschr Geneeskd 2003; 147: 561-565.
12. Joseph HA, Shrestha-Kuwahara R, Lowry D, et al. Factors influencing health care workers' adherence to work site tuberculosis screening and treatment policies. Am J Infect Control 2004; 32: 456-461.
13. Lumb R, Bastian I, Crighton T, et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2003. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell 2004; 28: 474-480.
14. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 3. Geneva: WHO, 2004. (Publication No.: WHO/HTM/TB/ 2004.343) http://www.who.int/tb/publications/2004/en/index.html (accessed Aug 2006).
15. Becerra MC, Bayona J, Freeman J, et al. Redefining MDR-TB transmission "hot spots". Int J Tuberc Lung Dis 2000; 4: 387-394.
16. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
17. Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000; 31 Suppl 3: S64-S67.
18. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45(RR-4): 1-18.
19. Tissot F, Zanetti G, Francioli P, et al. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217.
20. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366: 1443-1451.
21. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004; 291: 2086-2091.
22. Brewer TF, Colditz GA. Bacille Calmette-Guerin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995; 20: 136-142.
23. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 47-59.
24. Lotte A, Wasz-Hockert O, Poisson N, et al. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984; 21: 107-193.
25. Bellet JS, Prose NS. Skin complications of Bacillus Calmette-Guerin immunization. Curr Opin Infect Dis 2005; 18: 97-100.
26. Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette-Guerin immunization in normal healthy adults. J Infect Dis 1994; 170: 476-479.
27. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357: 2017-2021.
28. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Resp Crit Care Med 2004; 170: 59-64.
29. Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170: 65-69.
30. Mazurek GH, Jereb J, Lobue P, et al; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15): 49-55.